GLP-1-Based Therapy for Diabetes: What You Do Not Know Can Hurt You

• Autores: Peter C. Butler, Sarah Dry, Robert Elashoff
• Localización: Diabetes care, ISSN-e 0149-5992, Vol. 33, Nº. 2, 2010, págs. 453-455
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Even if this is a relatively small risk (which we do not know), how many of us practicing physicians would choose a therapeutic strategy for ourselves with insight into the potential for this risk? Since metformin has been shown to decrease the risk of pancreatic cancer, at the least we would suggest that GLP-1-based medications should be reserved for patients taking metformin.